Literature DB >> 19714488

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Ophira M Ginsburg1, Mohammad R Akbari, Zeba Aziz, Robert Young, Henry Lynch, Parviz Ghadirian, Andre Robidoux, Julian Londono, Gonzalo Vasquez, Magda Gomes, Mauricio Magalhaes Costa, Constantine Dimitrakakis, Gustavo Gutierrez, Robert Pilarski, Robert Royer, Steven A Narod.   

Abstract

Germ-line mutations in the TP53 gene are rare, but predispose women to a range of cancer types, including early-onset breast cancer. Breast cancers in women from families with the Li-Fraumeni syndrome often occur before age 30. The prevalence of deleterious TP53 mutations in unselected women with early-onset breast cancer is not precisely known. If mutations were found to be sufficiently common, it might be prudent to offer genetic testing to affected women in this age group. We screened the entire TP53 gene in the germ-line DNA from 95 women of various ethnic groups who were diagnosed with breast cancer before age 30, and who had previously been found to be negative for BRCA1 and BRCA2 mutations. No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19714488     DOI: 10.1007/s10689-009-9287-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  31 in total

1.  Improved splice site detection in Genie.

Authors:  M G Reese; F H Eeckman; D Kulp; D Haussler
Journal:  J Comput Biol       Date:  1997       Impact factor: 1.479

2.  BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.

Authors:  Fiona Lalloo; Jennifer Varley; Anthony Moran; David Ellis; Lindsay O'dair; Paul Pharoah; Antonis Antoniou; Roger Hartley; Andrew Shenton; Sheila Seal; Barbara Bulman; Anthony Howell; D Gareth R Evans
Journal:  Eur J Cancer       Date:  2006-04-27       Impact factor: 9.162

3.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

4.  BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.

Authors:  Maria Lourdes De Leon Matsuda; Alexander Liede; Elaine Kwan; Cynthia A Mapua; Eva Maria C Cutiongco; Alex Tan; Ake Borg; Steven A Narod
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

5.  Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.

Authors:  Lawrence R Dearth; Hua Qian; Ting Wang; Timothy E Baroni; Jue Zeng; Stephanie W Chen; Sun Young Yi; Rainer K Brachmann
Journal:  Carcinogenesis       Date:  2006-07-21       Impact factor: 4.944

6.  Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library.

Authors:  Kazuko Shiraishi; Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Masato Sakayori; Takanori Ishida; Motohiro Takeda; Ryunosuke Kanamaru; Noriaki Ohuchi; Chikashi Ishioka
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

7.  Follow-up study of twenty-four families with Li-Fraumeni syndrome.

Authors:  J E Garber; A M Goldstein; A F Kantor; M G Dreyfus; J F Fraumeni; F P Li
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

8.  Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients.

Authors:  G Keller; H Vogelsang; I Becker; S Plaschke; K Ott; G Suriano; A R Mateus; R Seruca; K Biedermann; D Huntsman; C Döring; E Holinski-Feder; A Neutzling; J R Siewert; H Höfler
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

9.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

10.  Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.

Authors:  Alexander Liede; Imtiaz A Malik; Zeba Aziz; Patricia de los Rios Pd; Elaine Kwan; Steven A Narod
Journal:  Am J Hum Genet       Date:  2002-08-13       Impact factor: 11.025

View more
  19 in total

1.  The tip of the iceberg: a countercurrents series.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

2.  Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.

Authors:  Muhammad U Rashid; Sidra Gull; Kashif Asghar; Noor Muhammad; Asim Amin; Ute Hamann
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

3.  Next generation sequencing is informing phenotype: a TP53 example.

Authors:  R O'Shea; R Clarke; E Berkley; C Giffney; M Farrell; E O'Donovan; D J Gallagher
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

Review 4.  Breast cancer in young women.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2012-06-26       Impact factor: 66.675

5.  Genomic Disparities in Breast Cancer Among Latinas.

Authors:  Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

6.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

7.  Examining the etiology of early-onset breast cancer in the Canadian Partnership for Tomorrow's Health (CanPath).

Authors:  Joy Pader; Robert B Basmadjian; Dylan E O'Sullivan; Nicole E Mealey; Yibing Ruan; Christine Friedenreich; Rachel Murphy; Edwin Wang; May Lynn Quan; Darren R Brenner
Journal:  Cancer Causes Control       Date:  2021-06-25       Impact factor: 2.506

8.  Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Authors:  Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

9.  No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.

Authors:  Judith Penkert; Brigitte Schlegelberger; Doris Steinemann; Dorothea Gadzicki
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

10.  Routine TP53 testing for breast cancer under age 30: ready for prime time?

Authors:  Jeanna M McCuaig; Susan R Armel; Ana Novokmet; Ophira M Ginsburg; Rochelle Demsky; Steven A Narod; David Malkin
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.